SCHEMBL23382810

SCHEMBL23382810

CCC1(OC(=O)Oc2ccc(C(=O)OCC(F)(F)C(=O)O)cc2)CCCC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 4/20 0.36
▸ NPSR1 Q6W5P4 3/20 0.36
▸ TDP1 Q9NUW8 2/20 0.36
▸ LMNA P02545 1/20 0.36
▸ KMT2A Q03164 4/20 0.36
▸ MEN1 O00255 3/20 0.36
▸ CYP2D6 P10635 2/20 0.36
▸ CYP1A2 P05177 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36
▸ CYP2C9 P11712 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36
▸ ADORA3 P0DMS8 1/20 0.34
▸ RARA P10276 3/20 0.33
▸ RARB P10826 3/20 0.33
▸ GAA P10253 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ HIF1A Q16665 1/20 0.33
▸ SLC6A3 Q01959 3/20 0.32
▸ SLC6A2 P23975 2/20 0.32
▸ SLC6A4 P31645 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23382811 0.99 ADORA3 (0.36) SMN1; SMN2NPSR1TDP1LMNAKMT2A
SCHEMBL23382999 0.89 NPSR1 (0.40) SMN1; SMN2NPSR1TDP1LMNAKMT2A
SCHEMBL23382804 0.88 RARA (0.35) SMN1; SMN2NPSR1TDP1LMNAKMT2A
SCHEMBL23382992 0.88 SMN1; SMN2 (0.39) SMN1; SMN2NPSR1TDP1LMNAKMT2A
SCHEMBL23382807 0.87 ADORA3 (0.36) SMN1; SMN2NPSR1TDP1LMNAKMT2A
SCHEMBL23382697 0.86 SMN1; SMN2 (0.39) SMN1; SMN2NPSR1TDP1LMNAKMT2A
SCHEMBL23382712 0.85 ADORA3 (0.39) SMN1; SMN2NPSR1TDP1LMNAKMT2A
SCHEMBL23382696 0.78 MAPK1 (0.38) SMN1; SMN2NPSR1TDP1LMNAKMT2A
SCHEMBL23382487 0.78 MAPK1 (0.40) SMN1; SMN2NPSR1TDP1LMNAKMT2A
SCHEMBL23382803 0.77 ELANE (0.56) SMN1; SMN2NPSR1TDP1KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11762287-B2 Onium salt compound, chemically amplified resist composition and patterning process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-09-19 — — US disclosed
US-11762287-B2 Onium salt compound, chemically amplified resist composition and patterning process SHIN-ETSU CHEMICAL CO., LTD. (JP) 2023-09-19 — — US disclosed
US-20210149301-A1 ONIUM SALT COMPOUND, CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS SHIN-ETSU CHEMICAL CO., LTD. (JP) 2021-05-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11762287-B2 Onium salt compound, chemically amplified resist composition and patterning process IDUA, SLC6A5, SLC6A9 SMN1; SMN2 3745/4885NPSR1 3275/4885TDP1 4190/4885
US-20210149301-A1 ONIUM SALT COMPOUND, CHEMICALLY AMPLIFIED RESIST COMPOSITION AND PATTERNING PROCESS IDUA, SLC6A5, SLC6A9 SMN1; SMN2 3745/4885NPSR1 3275/4885TDP1 4190/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback